MAPK1 and liver cancer: The 5‐HT7R antagonist SB258719 can effectively inhibit the proliferation of liver cancer cells [255]; SB‐258719 also inhibits the growth of xenograft tumors in patients with primary liver cancer [256, 345], modulates cytokine release from DCs, and inhibits ERK signaling in T cells [341].